Carvalhaes Cecilia G, Sader Helio S, Streit Jennifer M, Mendes Rodrigo E
JMI Laboratories, North Liberty, IA, USA.
JAC Antimicrob Resist. 2022 Sep 5;4(5):dlac088. doi: 10.1093/jacamr/dlac088. eCollection 2022 Oct.
The Surveillance of Tedizolid Activity and Resistance (STAR) programme monitored the tedizolid activity against , , , and group. We evaluated the antimicrobial susceptibility of 47 400 unique Gram-positive clinical isolates from the STAR programme collected from USA (21 243), Europe (17 674), Asia-Pacific (4954) and Latin America (3529) medical centres (2015-19).
All isolates were tested for susceptibility by reference broth microdilution method. WGS and analysis were performed on linezolid-non-susceptible (NS) isolates.
Tedizolid was active against ≥99.9% of (100.0% of MSSA and >99.9% of MRSA), , , and group isolates, with MIC values ranging from 0.12 to 0.25 mg/L and MIC values of 0.25 mg/L. Linezolid, vancomycin and daptomycin were also active agents against these organisms. Tedizolid inhibited all VRE and 73.1% of linezolid-NS isolates. Ampicillin and daptomycin retained 100.0% activity against VRE and linezolid-NS isolates. Linezolid-NS isolates carried mostly the gene. G2576T alterations in the 23S rRNA were observed in one linezolid-NS isolate and one linezolid-NS isolate.
No resistance trends were observed for tedizolid during the study period.
泰地唑胺活性与耐药性监测（STAR）项目监测了泰地唑胺对 、 、 、 和 菌属的活性。我们评估了从STAR项目中收集的47400株来自美国（21243株）、欧洲（17674株）、亚太地区（4954株）和拉丁美洲（3529株）医疗中心（2015 - 2019年）的独特革兰氏阳性临床分离株的抗菌药敏性。
所有分离株均通过参考肉汤微量稀释法进行药敏试验。对利奈唑胺不敏感（NS）的分离株进行全基因组测序（WGS）和 分析。
泰地唑胺对≥99.9%的 （100.0%的甲氧西林敏感金黄色葡萄球菌和>99.9%的甲氧西林耐药金黄色葡萄球菌）、 、 、 和 菌属分离株有活性，其MIC值范围为0.12至0.25 mg/L， 的MIC值为0.25 mg/L。利奈唑胺、万古霉素和达托霉素对这些微生物也是活性药物。泰地唑胺抑制了所有耐万古霉素肠球菌（VRE）和73.1%的利奈唑胺不敏感 分离株。氨苄西林和达托霉素对VRE和利奈唑胺不敏感 分离株的活性保持为100.0%。利奈唑胺不敏感 分离株大多携带 基因。在一株利奈唑胺不敏感 分离株和一株利奈唑胺不敏感 分离株中观察到23S rRNA的G2576T改变。
在研究期间未观察到泰地唑胺的耐药趋势。
